Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information remained secret.
Category: Eisai Co Ltd
-
New Drug Approved for Early Alzheimer’s
The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
-
Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug
The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.
-
FDA Makes Alzheimer’s Drug Leqembi Widely Accessible
The F.D.A. gave full approval to the drug, but added a black-box warning about safety risks. Medicare said it would cover most of the high cost.
-
F.D.A. Approves New Treatment for Early Alzheimer’s
The New York Times – Business:The drug, Leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. Still, data suggests it is more promising than the small number of other available treatments.
-
Alzheimer’s Drug May Benefit Some Patients, New Data Shows
The New York Times – Business:The drug, lecanemab, made by Eisai and Biogen, also carried risks of brain swelling and bleeding and should be studied further, a report of the findings said.